FPH Stock Chart & Stats
AU$32.68
AU$0.65(1.96%)
At close: 4:00 PM EDT
AU$32.68
AU$0.65(1.96%)
Day’s Range― - ―
52-Week RangeAU$26.51 - AU$40.15
Previous CloseN/A
Volume155.49K
Average Volume (3M)475.46K
Market Cap
AU$23.32B
Enterprise ValueAU$21.78B
Total Cash (Recent Filing)AU$461.10M
Total Debt (Recent Filing)AU$146.10M
Price to Earnings (P/E)61.1
Beta0.85
Next Earnings
Nov 25, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend Yield1.03%
Share Statistics
EPS (TTM)0.80
Shares Outstanding588,265,440
10 Day Avg. Volume444,940
30 Day Avg. Volume475,456
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)10.37
Price to Sales (P/S)9.38
P/FCF Ratio44.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$40.72Price Target Upside24.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.77
Revenue Forecast (FY)AU$2.08B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelRecurring-use consumables create replenishment demand alongside installed equipment, supporting revenue visibility beyond individual hardware purchases. Hospital patient volumes and ongoing homecare replacement needs can help sustain customer relationships, repeat sales, and cash generation over multiple periods.
Strong Growth And Margin ExpansionBroad-based revenue and profit growth, together with substantial gross and operating margin expansion, indicates improved operating leverage and product execution. If sustained, stronger profitability provides resources for research, capacity expansion, and continued investment in the company’s respiratory-care franchise.
Conservative Balance Sheet And Strong Cash FlowA net-cash position and very low gearing provide financial flexibility to fund capacity, R&D, and strategic infrastructure without relying heavily on borrowing. Strong operating and free cash flow also support dividends and give the company resilience when demand or currency conditions fluctuate.
Bears Say
Tariffs And Logistics Cost PressureTariffs and freight-related surcharges directly pressure gross margin and may persist through FY27, making earnings more dependent on continuous-improvement savings. If policy or logistics costs worsen, the company could face sustained profitability pressure or need to adjust pricing and sourcing.
Hospital Hardware Growth May NormalizeThe exceptional hospital hardware performance included pent-up demand, creating a difficult comparison for the next several quarters. A material slowdown would reduce overall revenue growth and could also limit the contribution from associated consumables and newly installed equipment.
Cash Flow Volatility And Elevated InvestmentAlthough current cash generation is strong, the historical swings in free cash flow show that working capital and investment requirements can materially affect conversion. Higher planned spending on land, buildings, and capacity increases near-term cash outflows and execution demands.
Fisher & Paykel Healthcare Corporation Limited News
FPH FAQ
What was Fisher & Paykel Healthcare Corporation Limited’s price range in the past 12 months?
Fisher & Paykel Healthcare Corporation Limited lowest share price was AU$26.51 and its highest was AU$40.15 in the past 12 months.
What is Fisher & Paykel Healthcare Corporation Limited’s market cap?
Fisher & Paykel Healthcare Corporation Limited’s market cap is AU$23.32B.
When is Fisher & Paykel Healthcare Corporation Limited’s upcoming earnings report date?
Fisher & Paykel Healthcare Corporation Limited’s upcoming earnings report date is Nov 25, 2026 which is in 30 days.
How were Fisher & Paykel Healthcare Corporation Limited’s earnings last quarter?
Fisher & Paykel Healthcare Corporation Limited released its earnings results on May 25, 2026. The company reported AU$0.349 earnings per share for the quarter, beating the consensus estimate of AU$0.348 by <AU$0.001.
Is Fisher & Paykel Healthcare Corporation Limited overvalued?
According to Wall Street analysts Fisher & Paykel Healthcare Corporation Limited’s price is currently Undervalued.
Does Fisher & Paykel Healthcare Corporation Limited pay dividends?
Fisher & Paykel Healthcare Corporation Limited pays a Notavailable dividend of AU$0.317 which represents an annual dividend yield of 1.03%. See more information on Fisher & Paykel Healthcare Corporation Limited dividends here
What is Fisher & Paykel Healthcare Corporation Limited’s EPS estimate?
Fisher & Paykel Healthcare Corporation Limited’s EPS estimate is 0.39.
How many shares outstanding does Fisher & Paykel Healthcare Corporation Limited have?
Fisher & Paykel Healthcare Corporation Limited has 588,265,440 shares outstanding.
What happened to Fisher & Paykel Healthcare Corporation Limited’s price movement after its last earnings report?
Fisher & Paykel Healthcare Corporation Limited reported an EPS of AU$0.349 in its last earnings report, beating expectations of AU$0.348. Following the earnings report the stock price went up 9.155%.
Which hedge fund is a major shareholder of Fisher & Paykel Healthcare Corporation Limited?
Currently, no hedge funds are holding shares in AU:FPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fisher & Paykel Healthcare Corporation Limited
Operating globally, Fisher & Paykel Healthcare Corporation Limited specializes in the development, manufacturing, and marketing of a wide array of medical device products and systems. These solutions are primarily utilized for acute and chronic respiratory care, during surgical procedures, and in the treatment of obstructive sleep apnea (OSA) within both hospital and home environments. Key offerings include the Airvo 2, a humidified nasal high flow system; Optiflow, for nasal high flow therapy; and the F&P 850 System, which facilitates noninvasive and invasive ventilation. The company also provides a comprehensive range of infant respiratory products, encompassing devices for resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Its extensive hospital product portfolio features humidification equipment, breathing circuits, chambers, various masks, nasal cannulas, surgical components, and different interfaces and accessories. For homecare, Fisher & Paykel Healthcare supplies masks, CPAP devices, data management software, humidifiers, and related accessories. Established in 1934, the company is headquartered in Auckland, New Zealand.
FPH Stock 12 Month Forecast
Average Price Target
AU$40.72
▲(24.62% Upside)
Technical Analysis
EBOS Group Limited
―
Pacific Edge Limited
―
Ryman Healthcare
―
TruScreen Group Ltd.
―
AFT Pharmaceuticals Ltd.
―